# JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

> **NCT06045585** · EARLY_PHASE1 · UNKNOWN · sponsor: **Guangdong Second Provincial General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** infusion of JY231 injection

## Key facts

- **NCT ID:** NCT06045585
- **Lead sponsor:** Guangdong Second Provincial General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-18
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045585, "JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06045585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*